β3GnT2-mediated N-glycosylation of EGFR and LDLR drives glioblastoma progression and can be targeted by AST-1306
Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a poor prognosis and limited therapeutic options. In this study, we identify β3GnT2 (β-1,3-N-acetylglucosaminyltransferase 2) as a critical driver of GBM progression and a potential therapeutic target. β3GnT2 is significantly upregulated...